Delavirdine mesylate

Delavirdine Mesylate is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV and AIDS. It is marketed under the trade name Rescriptor by pharmaceutical company Pfizer.

Pharmacology

Delavirdine mesylate works by inhibiting the action of reverse transcriptase, an enzyme crucial to the replication of HIV. By blocking this enzyme, delavirdine mesylate prevents the virus from multiplying, thereby reducing the amount of virus in the body.

Clinical Use

Delavirdine mesylate is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is not a cure for HIV or AIDS, but it can help to control HIV infection and decrease the risk of developing AIDS and AIDS-related illnesses.

Side Effects

Common side effects of delavirdine mesylate include rash, fatigue, headache, and nausea. Serious side effects can include liver problems and severe skin reactions.

Drug Interactions

Delavirdine mesylate can interact with a number of other medications, including certain antifungal medications, antibiotics, and other antiretroviral drugs. It is important for patients to inform their healthcare provider of all medications they are currently taking.

Dosage

The recommended dosage of delavirdine mesylate is 400 mg three times a day. The tablets should be swallowed whole and taken with or without food.

See Also

• Non-nucleoside reverse transcriptase inhibitors
• Antiretroviral therapy
• HIV/AIDS

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian